Crescent Biopharma Grants Equity Awards
Analysis based on 8 articles · First reported May 29, 2026 · Last updated Jun 11, 2026
The market may view these equity inducement awards positively for GT Biopharma, as they are designed to attract and retain talent, which can contribute to the company's long-term growth and innovation. This could lead to a slight positive sentiment for GT Biopharma's stock.
GT Biopharma, a clinical-stage biotechnology company, announced two separate grants of equity inducement awards to non-executive employees. On May 28, 2026, the company approved options to purchase 16,950 shares at an exercise price of $21.47. On June 10, 2026, another grant of options for 23,550 shares was approved with an exercise price of $17.57. These awards, made under the GT Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, are material to the employees' acceptance of employment and are intended to attract and retain talent. The options have a 10-year term and vest over time, subject to continuous service.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard